<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A47827B6-E971-4162-AB04-03E681A24620"><gtr:id>A47827B6-E971-4162-AB04-03E681A24620</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Overton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12018%2F25"><gtr:id>FBC225C2-288B-4DEE-AE28-FDA8A62F050A</gtr:id><gtr:title>Computational studies of phenotypic plasticity in development, metastasis and drug response; towards new clinical tools</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12018/25</gtr:grantReference><gtr:abstractText>We work to understand how cancer cells can spread around the body (metastasis) and how they become resistant to treatment with drugs; these factors cause the overwhelming majority of cancer deaths. We also develop software to inform clinical decision-making, for example to predict which patients will respond to a particular treatment. Together, these approaches help to develop better and more effective cancer medicine.
We know that cells are organised and controlled by complex interactions between many individual parts (molecules), and so inherently form intricate networks. The properties of these networks underlie virtually every aspect of cell function.
We map and analyse the messages passed, or information flow, amongst molecules by integrating billions of data points that describe key components such as DNA and proteins. Statistical inference, including machine learning, lets the data do the talking in order to reveal the molecular logic that controls health and disease. Indeed, computers are vital to modern biology, which interprets large datasets to gain insight into complex systems.
There is still a lot to discover about what makes the difference between patients that survive or succumb to cancer. However, we have encouraging results in subtypes of renal and breast cancers that may lead to diagnostic tools necessary for personalized medicine and provide direction in the search for more effective treatments.</gtr:abstractText><gtr:technicalSummary>We study molecular control of phenotype in epithelial remodelling and drug resistance to inform cancer medicine and fundamental biology.
Major interests:
1. Understanding molecular control and consequences of cell phenotypic plasticity in metastasis and drug resistance.
2. Developing more effective approaches for cancer patient stratification.
3. Generation of novel algorithms, techniques and computational workflows in line with 1 and 2 the above.
The spread of cells from a primary tumour to a secondary site remains one of the most life-threatening pathological events. Epithelial-Mesenchymal Transition (EMT) is a cell programme involving loss of cell-cell adhesion, gain of motility, invasiveness and survival; these properties are fundamental for metastasis. Epithelial remodelling is also crucial for development (e.g. gastrulation). Reactivation of a programme resembling EMT is a credible mechanism for key aspects of the invasion-metastasis cascade and an MET-like process may produce the (re)differentiation frequently observed in secondary tumours. Indeed, oncofetal signalling pathways (e.g. Hedgehog, Wnt, TGF-beta) activate EMT, and promote metastasis in multiple cancers.
Navigating from molecular measurements to phenotype implies understanding gene function (including gene products). However, many coding genes are poorly characterised, but coordinately regulated (e.g. in differentiation). Furthermore, new functions continue to be discovered even for deeply studied genes, and most noncoding genes are not well understood (e.g. lncRNA, miRNA). Thus, a substantial portion of gene function is uncharted. Data driven networks provide useful abstractions to fill these knowledge gaps, enabling testing and generation of mechanistic hypotheses. Indeed, understanding control of phenotype intrinsically implies modelling. 
We have developed systems-wide gene networks and are using these to investigate subtypes, stages and fingerprints of EMT/MET in different contexts (e.g. cardiac cushions, neural crest); additionally to identify new EMT players, pathway crosstalk and drivers of metastasis (eg colorectal, breast cancers). Collaborative experimental work (RNAi) has validated all predictions tested to date. We also infer small scale networks combining ex vivo immunohistochemical and clinical measurements (renal, ovarian, breast cancers). These models integrate carefully selected datasets to represent the specific biological/clinical context of interest. Therefore, this work involves integration of multiple datasets (e.g. ChIP-seq, microarray, proteomic) for machine learning and graph theoretic/statistical analyses. Supervised as well as unsupervised learning techniques are employed, including support vector machine and information-theoretic approaches (e.g. conditional mutual information). Prediction performance is assessed by rigorous benchmarking with blind test data.
We develop novel algorithms where required to advance biological understanding, for example we are working on methods to enable systems-wide dynamic modelling of renal cancer drug resistance to inform design of candidate combination therapies. We also make methods widely accessible (e.g. www.tmanavigator.org).
We collaborate closely with clinical colleagues and aim to translate results into medical practise. For example, we are currently working on a method to predict response of clear cell renal cell carcinoma patients to therapy (Sutent).</gtr:technicalSummary><gtr:fund><gtr:end>2017-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>348034</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vanderbilt-Ingram Cancer Center</gtr:department><gtr:description>Partnership with Vanderbilt Medical School</gtr:description><gtr:id>3674D018-158C-40E8-9A44-2834F7179763</gtr:id><gtr:impact>FCO UK-US Collaboration Development Fund award. 
Carnegie Trust Larger Collaborative grant.

Multidisciplinary collaboration involving:
Functional Genomics
Machine Learning
Biophysics
Systems Biology
Mathematical Biology
Cancer medicine &amp;amp; surgery
Molecular biology
Biochemistry</gtr:impact><gtr:outcomeId>Mqr62Vw8vg8-1</gtr:outcomeId><gtr:partnerContribution>A collaborator visited my group for 1 week in November 2012 supported by a joint application to the FCO UK-US Collaboration Development Fund. Prof. Lopez also contributed flights and accommodation for my PhD student to visit his group for 2 weeks in July 2012. 

Profs Peter Clark and Igor Puzanov are providing data and clinical material but this has not yet resulted in tangible output.

Vanderbilt are contributing person time, tools (e.g. PySB) and data.</gtr:partnerContribution><gtr:piContribution>I visited Vanderbilt medical school for 3 weeks in 2013 supported by the Marie Curie COFUND. My group are contributing person time, tools and data. I also won funding as PI from Carnegie trust which included bringing Prof Peter Clark to visit Scotland for 1 week in 2014 and was host applicant on the FCO UK-US Collaboration Development Fund for a 1 week visit by Prof Carlos Lopez in 2012.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Research video</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1B6985B8-705E-46FC-BA49-C71B217E2917</gtr:id><gtr:impact>A video was made that summarises my group's research interests for a non-specialist audience.

The video received positive comments in social media.

Positive comments and interest from academic colleagues.</gtr:impact><gtr:outcomeId>iN6mFDhainB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nutshellvideos. ed.ac.uk/ian-overton-network-medicine</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair of RSE Young Academy of Scotland Open Data Working Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B718E38-7036-4965-8E93-3F9CD842FA83</gtr:id><gtr:impact>Publications, available from the RSE Young Academy of Scotland website:
http://www.youngacademyofscotland.org.uk/our-work/open-data.html

As noted above these were submitted to the HEFCE call for advice and the Royal Society call for evidence.

Influence on HEFCE/RCUK policy on open access and open data.

Influence on the Royal Society (London) policy document on 'Science as an Open Enterprise'

Influence on Global Young Academy position statement on Open Science.

Influence on European Commission Science Policy.</gtr:impact><gtr:outcomeId>o1mLvADo9FP</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.youngacademyofscotland.org.uk/our-work/open-data.html</gtr:url><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit to IGMM (Broughton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5C8FF482-3885-4DC6-8CCA-EB624CE86239</gtr:id><gtr:impact>42 pupils attended a live demonstration of computational biology research (2012), which sparked questions and discussions afterwards. This was part of a visit to the institute that included talks and six live demonstrations.

Very positive feedback from pupils and teachers, continuing relationship with the school.</gtr:impact><gtr:outcomeId>NJvUqmp5KtN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>39999</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Molecular risk stratification of renal cancer relapse and treatment response</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Carnegie Trust</gtr:fundingOrg><gtr:fundingRef>50115</gtr:fundingRef><gtr:id>F96A961E-6CF9-4582-B5A5-E1769360C6F2</gtr:id><gtr:outcomeId>5447b4c6e526e4.36963119</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Welcome Trust-UoE Institutional Strategic Support Fund</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>494CFFFC-1A0D-4322-9BD9-053AC3F1AFDC</gtr:id><gtr:outcomeId>56deea8d4a67d1.35292780</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2012 UK-US Collaboration Development Award</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Foreign and Commonwealth Office (FCO)</gtr:fundingOrg><gtr:id>D16F4475-AB81-4C2F-8CE2-A1E599047C3B</gtr:id><gtr:outcomeId>nM4m5wAJ7HZ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300626</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer UK</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG14-006</gtr:fundingRef><gtr:id>0CD57678-D097-4ACB-92D4-FF898E2FD4DB</gtr:id><gtr:outcomeId>56deeb812966e7.40933211</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50169</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept (University of Edinburgh Award)</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C0E94605-D129-4503-9A47-768CDD0C46D6</gtr:id><gtr:outcomeId>56deec281a64c3.07843622</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method for risk stratification of metastatic clear cell renal cell carcinoma, using the protein markers and CDH2, EPCAM, MTOR. The method compares well with established clinicopathological nomograms on a geographically separated validation cohort.</gtr:description><gtr:grantRef>MC_UU_12018/25</gtr:grantRef><gtr:id>BE5EEBA8-F044-4F22-8485-B523726881A9</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56df0280e25110.28962310</gtr:outcomeId><gtr:patentId>PCT/GB2015/051345</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for risk stratification of renal cancer patients</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Submission to EUROPEAN Commision Consultation on Science 2.0 - Science in Transition</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>D0174A49-7772-4B8C-9677-CF40169C65AA</gtr:id><gtr:impact>Recommendations made directly by the YAS Open Data working group, which I chair, are implemented into the European Commission policy brief draft; indeed YAS is named in the document (p5) &amp;quot;Several organisations (YAS, RC Norway, Royal Society, and NWO) stressed the importance of open data in their position statements, and they discussed the importance of encouraging activities such as data creation, curation and sharing&amp;quot;. Another example (of several) where recommendations are identified in the policy brief draft: &amp;quot;Policy recommendations from academies, learned societies and research funders... Highlight best practices and ethical behaviour in data management.&amp;quot; see:
https://scienceintransition.files.wordpress.com/2014/10/draft-policy-brief-science-2-0-workshop-madrid-04-december-2014.pdf</gtr:impact><gtr:outcomeId>5449322b8c4df4.49270994</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://ec.europa.eu/research/consultations/science-2.0/consultation_en.htm</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited interviewee for ESRC funded study on Open Science and Innovation in Contemporary Systems and Synthetic Biology</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E2D5CA3C-C969-46D6-B577-F15D81E5AAD3</gtr:id><gtr:impact>Informed a Open Science policy meeting with research funders (incl. MRC, BBSRC, HEFCE, Wellcome, TSB), on March 10th 2014.</gtr:impact><gtr:outcomeId>5447e51ef22f58.66375024</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>TMA Navigator is a collection of tools for analysing tissue microarray (TMA) data directly from a web browser. The latter part of the TMA Navigator name derives from the themes of Networks, Analysis and Visualisation. The tools are also useful for analysis of multiple other data-types (e.g. Reverse Phase Protein Array)</gtr:description><gtr:id>7509BF98-95BA-4D70-AF3E-2BF03C2BDB37</gtr:id><gtr:impact>The TMA Navigator tools have been used as part of clinical research programmes at the Universities of Edinburgh and St. Andrews. They also support research at other institutions nationally (e.g. NIMR) and internationally (e.g. Vanderbilt, USA).</gtr:impact><gtr:outcomeId>PonpvevgkHz</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TMA Navigator</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://www.tmanavigator.org</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>TMA Navigator is a suite of tools developed for Tissue Microarray data, including network inference, molecular stratification and survival analysis.</gtr:description><gtr:id>D3BFF511-895C-4347-991C-71A074748DD2</gtr:id><gtr:impact>TMA Navigator is used widely and runs hundreds of analyses per month. TMA Navigator has been used as part of clinical research programmes at the Universities of Edinburgh and St. Andrews. It also supports research at other institutions nationally (e.g. NIMR) and internationally (e.g. Vanderbilt, USA).</gtr:impact><gtr:outcomeId>5447dc79e60e08.15152644</gtr:outcomeId><gtr:title>TMA Navigator</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:url>http://www.tmanavigator.org</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1967D070-2E66-4EA7-B29C-28BD61D4DA64</gtr:id><gtr:title>Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5cdb8db97487669926edadc17458821"><gtr:id>c5cdb8db97487669926edadc17458821</gtr:id><gtr:otherNames>O'Neill JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>5a328b211250b8.60760357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21781D9C-66C9-43A2-BC9F-1911C14A1FD2</gtr:id><gtr:title>Addressing statistical biases in nucleotide-derived protein databases for proteogenomic search strategies.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4517e9e4788383be422fd2c001ea87b3"><gtr:id>4517e9e4788383be422fd2c001ea87b3</gtr:id><gtr:otherNames>Blakeley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>pm_24463_23_23025403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BAE54B-112F-4BF8-BCDC-D1BE4E414ABB</gtr:id><gtr:title>TMA Navigator: Network inference, patient stratification and survival analysis with tissue microarray data.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d6e552e7b9f574a3d1c18bda73b24b6"><gtr:id>1d6e552e7b9f574a3d1c18bda73b24b6</gtr:id><gtr:otherNames>Lubbock AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_24463_23_23761446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C4226FB-C33B-4BCE-AD25-72E21168CD37</gtr:id><gtr:title>Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/719bfd5964444590682cadfee22b78aa"><gtr:id>719bfd5964444590682cadfee22b78aa</gtr:id><gtr:otherNames>Lubbock ALR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a34fd39659727.05670231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD58BA63-1533-4501-80DD-22DE98C13495</gtr:id><gtr:title>Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c37f799329bbe36bda8a1ed60d551c"><gtr:id>72c37f799329bbe36bda8a1ed60d551c</gtr:id><gtr:otherNames>Stewart GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56a78c1eebc849.73201492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82A5EF24-0A03-4B33-AC34-15411B05DF7D</gtr:id><gtr:title>The DATA Bonanza - Improving Knowledge Discovery in Science, Engineering, and Business</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a9e0d8729620d00d88750bd5c4feb03"><gtr:id>2a9e0d8729620d00d88750bd5c4feb03</gtr:id><gtr:otherNames>Han L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-1-118-39864-7</gtr:isbn><gtr:outcomeId>E8FhF74M9Fv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6853D4C-8B1D-4065-BC4E-120D0E7472F3</gtr:id><gtr:title>The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_24463_23_24137011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B14CB2E3-A0AC-48FA-B190-2C5E306A9D60</gtr:id><gtr:title>The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f2336890aa43969542a2a3c8b1d4702"><gtr:id>7f2336890aa43969542a2a3c8b1d4702</gtr:id><gtr:otherNames>O'Mahony FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>pm_24463_23_23380956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C29CED77-7C66-4206-94A8-5BD5B390B92C</gtr:id><gtr:title>Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c37f799329bbe36bda8a1ed60d551c"><gtr:id>72c37f799329bbe36bda8a1ed60d551c</gtr:id><gtr:otherNames>Stewart GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5447b1afba24b3.17320371</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12018/25</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>